Fellow
Mo MA
CEO, Eurekabio
MA Mo, an entrepreneur from HKUST EEE Department, has founded Eurekabio in 2014, along with XUE Bofu, another graduate from the Life Science department. They have a passion for innovation and a deep understanding of the cross-disciplinary collaboration and apply it in the biotechnology industry, providing innovative and cutting-edge solutions to the industry. The company's team of experts and state-of-the-art technology are poised to make a significant impact in the field of biotechnology.
Company Description
Eurekabio stands as a pioneering force in the realm of cell and gene therapy, serving as a leading upstream core supplier. Our primary focus lies in the research and development of pivotal biotechnology and autonomous equipment in the field of gene and cell therapy (CGT). By seamlessly integrating automation technology, artificial intelligence, and diverse disciplines with biotechnology, we have successfully addressed crucial technological challenges in gene therapy, cell therapy, life science, and pharmaceutical R&D.
Through the synergies of cross-disciplinary collaboration and technological innovation, Eurekabio has consistently pushed the boundaries of therapy. Eurekabio has brought forth advanced cellular drug production solutions and the EuLV lentiviral vector platform. These breakthroughs, including high-titer stable lentiviral vector packaging and producer cell lines, are poised to play a pivotal role in the global commercialization of CGT drugs. Our ultimate aim is to bring tangible benefits to patients worldwide by ushering in a new era of advanced and accessible therapies.